Physician

Mark Evan Stevens, M.D.

According to 2025 Medicare claims, Mark Stevens, M.D. (NPI: 1629399001) practices allergy/immunology in the St. George, UT market, with the plurality of this provider's patient population coming from Washington, UT. This provider's primary affiliated billing organization is IHC HEALTH SERVICES INC (NPI: 1093958605; TIN: 94-2854057) and primary practice location at 84770-3705. Stevens is affiliated with the Aledade 201 National MSSP (ACO ID: A5522) and Castell Accountable Care, LLC (ACO ID: D0136), participating under both the MSSP and REACH models.

Stevens' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 266 traditional Medicare patients, billed 15,039 HCPCS/CPT codes, and received $374,673 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,862 prescription claims across 367 beneficiaries totaling $632,036 in drug costs, led by Nucala (Mepolizumab). DME data shows 727 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $24,826 to $374,673. Similarly, Part D prescription costs have moved sharply higher in recent years, from $31,762 to $632,036. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $536 to $19,840.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	62	1,446	$24,826
2016	152	4,981	$77,093
2017	209	8,607	$178,445
2018	254	9,146	$208,622
2019	256	5,869	$142,610
2020	270	9,614	$225,408
2021	282	9,455	$190,650
2022	276	11,201	$254,137
2023	304	14,766	$328,455
2024	266	15,039	$374,673

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	56	245	$31,762
2016	114	479	$42,664
2017	143	649	$84,010
2018	182	1,009	$122,961
2019	224	1,307	$262,764
2020	262	1,641	$360,633
2021	291	1,736	$333,080
2022	295	1,695	$418,669
2023	345	1,955	$541,349
2024	367	1,862	$632,036

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	76	$33,945
2019	N/R	136	$101,475
2020	26	483	$388,837
2021	42	523	$516,733
2022	45	509	$534,479
2023	51	663	$712,412
2024	53	727	$817,328

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	68	68	$116
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	175	243	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	82	97	$57
G0009	Administration of pneumococcal vaccine	38	38	$31
95004	Test for allergy using allergenic extract	38	1,782	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Nucala	Mepolizumab	19	756	$157,395
Gammaked	Immune Globul G/Gly/Iga Avg 46	13	364	$100,612
Xolair	Omalizumab	25	700	$76,155
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	1,260	$25,529
Breo Ellipta	Fluticasone/Vilanterol	23	1,410	$18,503

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1559	Injection, immune globulin (hizentra), 100 mg	N	13	154	$504,334
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	41	$142,886
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	22	$59,275
J1558	Injection, immune globulin (xembify), 100 mg	N	N/R	13	$46,306
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	15	$45,015

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Mark Evan Stevens, M.D.?

Tedicare shows public-source Medicare data for Mark Evan Stevens, M.D. (NPI 1629399001), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark Evan Stevens, M.D. have ACO affiliation data?

Mark Evan Stevens, M.D. is shown with ACO affiliation data for Aledade 201 National MSSP (MSSP, ACO ID A5522) and Castell Accountable Care, LLC (REACH, ACO ID D0136).

What billing organization is linked to Mark Evan Stevens, M.D.?

Mark Evan Stevens, M.D. is linked to IHC HEALTH SERVICES INC (billing NPI 1093958605) in the available physician profile data.

Does Mark Evan Stevens, M.D. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.